Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety and Efficacy Pilot Trial of the Anti-Viral and Anti-Tumor Activity of Velcade Combined with (R)ICE in Subjects with EBV and/or HHV-8 Positive Relapsed/ Refractory AIDS-Associated Non-Hodgkin's Lymphoma

Trial Profile

Safety and Efficacy Pilot Trial of the Anti-Viral and Anti-Tumor Activity of Velcade Combined with (R)ICE in Subjects with EBV and/or HHV-8 Positive Relapsed/ Refractory AIDS-Associated Non-Hodgkin's Lymphoma

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 17 Sep 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bortezomib (Primary) ; Carboplatin; Dexamethasone; Etoposide; Ifosfamide; Rituximab
  • Indications Non-Hodgkin's lymphoma
  • Focus Adverse reactions; Therapeutic Use

Most Recent Events

  • 06 Dec 2016 Results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
  • 07 May 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
  • 02 Feb 2015 Planned End Date changed from 1 Jul 2015 to 1 Apr 2015 according to ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top